WOBURN, Mass. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell ® technology has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for reducing moderate to severe symptoms of chemotherapy induced peripheral

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO, NUROW) announced today that the CE (Conformité Européenne ) Certificate for Quell ® has been received from TŰV SŰD Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new products.

NeuroMetrix Receives 510(k) Clearance for SENSUS™ Pain Management Device WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 6, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced

WALTHAM, Mass. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported that it had achieved the second development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.

WALTHAM, Mass. , June 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it had achieved the first development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Quell has been featured in several forums during this year's International Consumer Electronics Show (CES). Among the highlights: NeuroMetrix President and Chief Executive Officer, Shai N.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today provided an update on its Quell ® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain. In addition to delivery of therapy, the device and its associated

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell ® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and

WALTHAM, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating

WOBURN, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US adults have chronic pain. People with chronic pain may also have low quality sleep, anxiety, depression,